

CITATION REPORT

List of articles citing

Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study

DOI: 10.3945/ajcn.113.068890

American Journal of Clinical Nutrition, 2014, 99, 535-42.

Source: <https://exaly.com/paper-pdf/59399011/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
283	The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. <i>Nutrients</i> , 2014 , 6, 5583-99	6.7	65
282	Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2015 , 7, 204-12	3.4	50
281	Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 15518-31	5.6	111
280	Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. 2014 , 34, 837-43		199
279	More evidence that probiotics may have a role in treating fatty liver disease. <i>American Journal of Clinical Nutrition</i> , 2014 , 99, 425-6	7	4
278	The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. 2015 , 114, 796-803		109
277	The effects of onion consumption on treatment of metabolic, histologic, and inflammatory features of nonalcoholic fatty liver disease. 2015 , 15, 25		23
276	Probiotics in Pediatric Liver Disease. 2015 , 49 Suppl 1, S33-6		9
275	Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future. <i>World Journal of Hepatology</i> , 2015 , 7, 2597-602	3.4	38
274	The Microbiome and Sustainable Healthcare. 2015 , 3, 100-29		29
273	Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2015 , 7, 559-65	3.4	29
272	Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 25168-98	6.3	76
271	Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , 2015 , 21, 3777-85	5.6	82
270	Immune Modulation by Probiotics. 2015 , 101-130		3
269	Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. 2015 , 48, 923-30		165
268	Probiotics. 2015 , 61, 259-90		28
267	New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. 2015 , 60 Suppl 2, S108-21		151

266	The growth potential for dairy probiotics. 2015 , 49, 16-22		48
265	Nonalcoholic Fatty Liver Disease Management: Dietary and Lifestyle Modifications. 2015 , 35, 318-37		19
264	A systematic review and meta-analysis of the prebiotics and synbiotics effects on glycaemia, insulin concentrations and lipid parameters in adult patients with overweight or obesity. 2015 , 34, 845-58		106
263	Ginger Supplementation in Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. <i>Hepatitis Monthly</i> , 2016 , 16, e34897	1.8	50
262	Prevention of Nonalcoholic Fatty Liver Disease (NAFLD) Progression to Nonalcoholic Steatohepatitis (NASH) by Modification of Lifestyle and Dietary Supplements. 2016 , 2,		1
261	Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. <i>International Journal of Molecular Sciences</i> , 2016 , 17, 481	6.3	70
260	Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	160
259	Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. <i>Nutrients</i> , 2016 , 8,	6.7	60
258	Synbiotics. 2016 , 811-822		3
257	Effects of Prebiotic and Synbiotic Supplementation on Inflammatory Markers and Anthropometric Indices After Roux-en-Y Gastric Bypass: A Randomized, Triple-blind, Placebo-controlled Pilot Study. 2016 , 50, 208-17		33
256	A Bugs Battle on Behalf of the Liver. 2016 , 23, 126-129		
255	The role of probiotics in the prevention of disease. 2016 , 14, 21-28		
254	Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease. 2016 , 61, 1365-74		72
253	Dietary supplementation in patients with alcoholic liver disease: a review on current evidence. 2016 , 15, 348-60		22
252	The effect of minimal dietary changes with raisins in NAFLD patients with non-significant fibrosis: a randomized controlled intervention. 2016 , 7, 4533-4544		13
251	Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities. 2016 , 39, 1830-45		97
250	Promising therapies for treatment of nonalcoholic steatohepatitis. 2016 , 21, 343-57		23
249	Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 1109-23	6.1	31

248	Adherence to the Dietary Approaches to Stop Hypertension (DASH) and risk of Nonalcoholic Fatty Liver Disease. 2016 , 67, 1024-9	50
247	Antibiotic Use in Animal Feed and its Impact on Antibiotic Resistance in Human Pathogens. 2016 , 145-164	1
246	Flaxseed supplementation in non-alcoholic fatty liver disease: a pilot randomized, open labeled, controlled study. 2016 , 67, 461-9	52
245	Targeting Dysbiosis for the Treatment of Liver Disease. 2016 , 36, 37-47	30
244	Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. 2016 , 20, 351-64	9
243	Gut Microbiota of Nonalcoholic Fatty Liver Disease. 2016 , 61, 1268-81	37
242	Mechanisms Linking the Gut Microbiome and Glucose Metabolism. 2016 , 101, 1445-54	100
241	Exercise and diet in the management of nonalcoholic fatty liver disease. 2016 , 65, 1172-82	37
240	Obesity. 2016 ,	4
239	Probiotics for people with hepatic encephalopathy. 2017 , 2, CD008716	48
238	Synbiotic supplementation and the effects on clinical and metabolic responses in patients with rheumatoid arthritis: a randomised, double-blind, placebo-controlled trial. 2017 , 117, 1095-1102	39
237	Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids. 2017 , 58, 1399-1416	66
236	Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. 2017 , 117, 662-668	107
235	Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. 2017 , 8, 240-252	85
234	Molecules, Systems and Signaling in Liver Injury. 2017 ,	
233	The Impact of Gut Microbiota on Liver Injury. 2017 , 251-283	
232	Prebiotic-Probiotic Relationship: The Genetic Fundamentals of Polysaccharides Conversion by Bifidobacterium and Lactobacillus Genera. 2017 , 237-278	7
231	Short-chain fatty acids, prebiotics, synbiotics, and systemic inflammation: a systematic review and meta-analysis. <i>American Journal of Clinical Nutrition</i> , 2017 , 106, 930-945	7 107

230	A study of the prebiotic-like effects of tomato juice consumption in rats with diet-induced non-alcoholic fatty liver disease (NAFLD). 2017 , 8, 3542-3552		16
229	Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis. 2017 , 26, 519-541		213
228	Effects of inulin-type fructans, galacto-oligosaccharides and related synbiotics on inflammatory markers in adult patients with overweight or obesity: A systematic review. 2017 , 36, 1197-1206		43
227	Pomegranate juice prevents development of non-alcoholic fatty liver disease in rats by attenuating oxidative stress and inflammation. 2017 , 97, 2327-2332		29
226	Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis. 2017 , 7, 130-137		33
225	Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. <i>Nutrients</i> , 2017 , 9,	6.7	100
224	Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. <i>Nutrients</i> , 2017 , 9,	6.7	793
223	Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2017 , 9,	6.7	47
222	Probiotic, Prebiotic, and Brain Development. <i>Nutrients</i> , 2017 , 9,	6.7	41
221	Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. 2017 , 4,		59
220	Prebiotic and Synbiotic Modifications of Beta Oxidation and Lipogenic Gene Expression after Experimental Hypercholesterolemia in Rat Liver. <i>Frontiers in Microbiology</i> , 2017 , 8, 2010	5.7	21
219	Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2017 , 23, 7495-7504	5.6	34
218	Effects of Probiotic and Prebiotic Supplementation on Leptin, Adiponectin, and Glycemic Parameters in Non-alcoholic Fatty Liver Disease: A Randomized Clinical Trial. <i>Middle East Journal of Digestive Diseases</i> , 2017 , 9, 150-157	1.1	43
217	Gut bacteria may control development of hepatocellular carcinoma. 2017 , 6, 417-419		5
216	Effects of synbiotic supplementation on metabolic parameters and apelin in women with polycystic ovary syndrome: a randomised double-blind placebo-controlled trial. 2018 , 119, 398-406		25
215	Future of Treatment for Nonalcoholic Steatohepatitis: Can the Use of Safe, Evidence-Based, Clinically Proven Supplements Provide the Answer to the Unmet Need?. 2018 , 63, 1726-1736		5
214	The effects of synbiotic supplementation on hormonal status, biomarkers of inflammation and oxidative stress in subjects with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. 2018 , 18, 21		29
213	Disruptions in gut microbial-host co-metabolism and the development of metabolic disorders. 2018 , 132, 791-811		23

212	Effects of Synbiotics on Anthropometric Indices of Obesity in Children. 2018 , 33, 118-126		3
211	The Effects of Onion Consumption on Prevention of Nonalcoholic Fatty Liver Disease. 2018 , 33, 75-80		18
210	Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. 2018 , 22, 175-187		21
209	Nicotinamide prevents sweet beverage-induced hepatic steatosis in rats by regulating the G6PD, NADPH/NADP and GSH/GSSG ratios and reducing oxidative and inflammatory stress. 2018 , 818, 499-507		16
208	Probiotics, prebiotics, synbiotics and insulin sensitivity. 2018 , 31, 35-51		105
207	Microbiota, Liver Diseases, and Alcohol. 2017 , 5,		12
206	Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. 2018 , 1864, 607-617		26
205	Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis. 2018 , 57, 2037-2053		23
204	Intestinal Microbiome and the Liver. 2018 , 37-65.e6		
203	Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2018 , 24, 331-338	6.9	15
202	Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. 2018 , 56, 855-867		21
201	Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. <i>Postgraduate Medical Journal</i> , 2018 , 94, 556-565	2	11
200	Microbiota, Liver Diseases, and Alcohol. 2018 , 187-212		1
199	Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease. 2018 , 71, 113-123		21
198	The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease. 2018 , 1061, 95-110		10
197	Obesity, Fatty Liver and Liver Cancer. 2018 ,		3
196	Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. 2018 , 148, 1276-1284		54
195	A Controlled Fermented Herbal Formula Ameliorates Non-alcoholic Hepatosteatorosis in HepG2 Cells and OLETF Rats. 2018 , 9, 596		9

194	Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis. 2018 , 76, 822-839		56
193	Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. <i>Frontiers in Microbiology</i> , 2018 , 9, 61	5-7	83
192	The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease. 2018 , 6,		10
191	Probiotic Supplementation in Morbid Obese Patients Undergoing One Anastomosis Gastric Bypass-Mini Gastric Bypass (OAGB-MGB) Surgery: a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. 2018 , 28, 2874-2885		22
190	Unmet needs in pediatric NAFLD research: what do we need to prioritize for the future?. 2018 , 12, 961-967		8
189	Changes in the immune system - the key to diagnostics and therapy of patients with non-alcoholic fatty liver disease. 2018 , 43, 231-239		12
188	Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. 2019 , 58, 1735-1745		44
187	Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 628-639	6.1	19
186	The effects of black seed supplementation on cardiovascular risk factors in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled clinical trial. 2019 , 33, 2369-2377		11
185	[Microbiome & NASH - partners in crime driving progression of fatty liver disease]. 2019 , 57, 871-882		2
184	Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial. <i>BMC Gastroenterology</i> , 2019 , 19, 133	3	44
183	A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach. 2019 , 13, 2917-2922		15
182	Effect of dietary intervention, with or without co-interventions, on inflammatory markers in patients with nonalcoholic fatty liver disease: a systematic literature review. 2019 , 77, 765-786		5
181	Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial. 2019 , 33, 2118-2125		19
180	Effect of probiotic supplementation in nonalcoholic steatohepatitis patients: PROBILIVER TRIAL protocol. 2019 , 20, 580		5
179	Probiotic, Prebiotic and Synbiotic Products in Human Health. 2019 ,		7
178	Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. 2019 , 12, 1756284819878046		20
177	Effect of N1115 and fructooligosaccharides in nonalcoholic fatty liver disease. 2019 , 15, 1336-1344		21

176	The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). 2019 , 76, 1541-1558		161
175	ESPEN guideline on clinical nutrition in liver disease. 2019 , 38, 485-521		202
174	Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. <i>American Journal of Clinical Nutrition</i> , 2019 , 110, 139-149	7	50
173	Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis. 2019 , 64, 3402-3412		33
172	The microbiome and cancer for clinicians. 2019 , 141, 1-12		50
171	Dietary Inflammatory Index and Odds of Colorectal Cancer and Colorectal Adenomatous Polyps in A Case-Control Study from Iran. <i>Nutrients</i> , 2019 , 11,	6.7	11
170	Ingestion of a Synbiotic Pasta by Those with Elevated Blood Sugar and Body Mass Index Results in Health Benefits. 2019 , 149, 1687-1689		
169	<i>Nigella sativa</i> and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Results from a randomized, double-blind, placebo-controlled, clinical trial. 2019 , 44, 204-209		13
168	Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). 2019 , 18, 416-421		28
167	Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease. <i>Nutrients</i> , 2019 , 11,	6.7	71
166	Spinach consumption ameliorates the gut microbiota and dislipaemia in rats with diet-induced non-alcoholic fatty liver disease (NAFLD). 2019 , 10, 2148-2160		15
165	The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD. 2019 , 7,		24
164	Prevalence of non-alcoholic fatty liver disease in patients with diabetes mellitus, hyperlipidemia, obesity and polycystic ovary syndrome: A cross-sectional study in north of Iran. 2019 , 13, 1591-1596		13
163	Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver?. 2019 , 244, 408-418		9
162	What are the main areas of focus to prevent or treat non-alcoholic fatty liver disease?. 2019 , 20, 271-277		2
161	Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. 2019 , 9, e017995		97
160	Polyphenol intakes and risk of impaired lipid profile, elevated hepatic enzymes and nonalcoholic fatty liver disease. 2019 , 49, 903-910		7
159	Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease. 2019 , 9, 5688		59

158	Legume intake and risk of nonalcoholic fatty liver disease. 2019 , 38, 55-60		7
157	Inflammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease: a randomized, double blind, placebo-controlled, clinical trial. 2019 , 12, 89		13
156	Dietary Interventions and Inflammatory Bowel Disease. 2019 , 33-42		
155	Effects of synbiotic supplement on LPS level in Thai smokers: A preliminary study. 2019 , 11, 16-21		
154	. 2019 ,		
153	Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?. <i>Nutrients</i> , 2019 , 11,	6.7	23
152	Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease. 2019 , 2019, 1484598		19
151	The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. 2019 , 31, 703-715		9
150	Enzymes in the Design of Functional Foods or Their Constituents. 2019 , 383-412		
149	Glycyrrhizic acid improving the liver protective effect by restoring the composition of Lactobacillus. 2019 , 52, 219-227		5
148	Green Bio-processes. 2019 ,		3
147	The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. 2019 , 73, 441-449		28
146	Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. 2019 , 13, 193-204		39
145	Inflammatory gene expression analysis after prebiotic, probiotic and synbiotic supplementation in experimental nonalcoholic fatty liver disease. 2019 , 49, 75-84		3
144	Galactose intake is related to nonalcoholic fatty liver disease. 2019 , 49, 359-367		3
143	Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD. 2019 , 59, 2494-2505		27
142	Efficacy of synbiotic supplementation in obesity treatment: A systematic review and meta-analysis of clinical trials. 2020 , 60, 584-596		33
141	Effect of probiotic and synbiotic supplementation on inflammatory markers in health and disease status: A systematic review and meta-analysis of clinical trials. 2020 , 39, 789-819		44

140	Association between habitual yogurt consumption and newly diagnosed non-alcoholic fatty liver disease. 2020 , 74, 491-499		11
139	Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. 2020 , 55, 142-158		41
138	Probiotics, prebiotics, and synbiotics: Current status and future uses for human health. 2020 , 173-190		5
137	The effects of <i>Bacillus coagulans</i> supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial. 2020 , 39, 53-60		9
136	Understanding the Role of Exercise in Nonalcoholic Fatty Liver Disease: ERS-Linked Molecular Pathways. 2020 , 2020, 6412916		2
135	Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH. 2020 , 13, 3861-3872		7
134	ESPEN practical guideline: Clinical nutrition in liver disease. 2020 , 39, 3533-3562		52
133	New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. <i>Nutrients</i> , 2020 , 12,	6.7	31
132	The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. 2020 , 17, 687-701		249
131	A Serum Metabolic Profiling Analysis During the Formation of Fatty Liver in Landes Geese via GC-TOF/MS. 2020 , 11, 581699		3
130	Gut metabolites and inflammation factors in non-alcoholic fatty liver disease: A systematic review and meta-analysis. 2020 , 10, 8848		25
129	Microbiote intestinal et stéatopathie métabolique. 2020 , 34, 130-140		
128	Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2020 , 12,	6.7	17
127	Treatment of non-alcoholic fatty liver disease - Current perspectives. 2020 , 39, 22-31		9
126	Combined cranberry supplementation and weight loss diet in non-alcoholic fatty liver disease: a double-blind placebo-controlled randomized clinical trial. 2020 , 71, 991-1000		4
125	Crosstalk between kidney and liver in non-alcoholic fatty liver disease: mechanisms and therapeutic approaches. 2020 , 1-15		4
124	Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?. 2020 , 158, 1881-1898		38
123	Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease. 2020 , 158, 1597-1610.e7		59

122	Probiotics as Live Bio-therapeutics: Prospects and Perspectives. <i>Microorganisms for Sustainability</i> , 2021 , 83-120	1.1	2
121	Advances in Probiotics for Sustainable Food and Medicine. <i>Microorganisms for Sustainability</i> , 2021 ,	1.1	2
120	Gut Microbiome and Diet. 2021 , 12-12		
119	The Role of Probiotics and Synbiotics on Hirsutism. 2021 , 7, 10		1
118	Synbiotics in Nutrition. 2021 , 149-161		1
117	Probiotic Fermentation of Konjac and Carob Pods <i>Ceratonia siliqua</i> and Observation of Related Antioxidant Activity. 2021 , 16, 18-30		
116	Human Gut Microbiota and the Influence of Probiotics, Prebiotics, and Micronutrients. 2021 , 271-271		0
115	Effects of synbiotic supplementation on serum adiponectin and inflammation status of overweight and obese breast cancer survivors: a randomized, triple-blind, placebo-controlled trial. 2021 , 29, 4147-4157		3
114	Inulin as a Clinical Therapeutic Intervention in Metabolic Associated Fatty Liver Disease. 1-13		
113	Synbiotics: safety and toxicity considerations. 2021 , 1107-1123		1
112	Molecular Mechanisms Linking Nonalcoholic Steatohepatitis to Cancer. 2021 , 17, 6-10		2
111	Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date. 2021 , 18,		3
110	Synbiotic Efficacy as Therapeutic Approach in Human Disease: A Review. 2021 , 44,		1
109	Mikrobiom und metabolische Fettlebererkrankung (MeFLD). 2021 , 17, 391-397		
108	Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases. 2021 , 9, 227-238		4
107	Probiotics, Pre-biotics and Synbiotics in the Treatment of Pre-diabetes: A Systematic Review of Randomized Controlled Trials. 2021 , 9, 645035		1
106	The Impact of Dietary Patterns and Nutrition in Nonalcoholic Fatty Liver Disease. 2021 , 50, 217-241		2
105	The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD. 2021 , 135, 111235		5

104	Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled, clinical trial. 2021 , 20, 35		9
103	Probiotics/Prebiotics in Viral Respiratory Infections: Implication for Emerging Pathogens. 2021 , 15, 112-136		5
102	Steatohepatitis in Children with Obesity.		
101	Combined intake of blueberry juice and probiotics ameliorate mitochondrial dysfunction by activating SIRT1 in alcoholic fatty liver disease. 2021 , 18, 50		3
100	Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	7
99	Does symbiotic supplementation which contains and fructooligosaccharide has favourite effects in patients with type-2 diabetes? A randomised, double-blind, placebo-controlled trial. 2021 , 1-8		1
98	Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. 2021 , 7, CD013157		2
97	The impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease. 2021 , 34, 477-482		2
96	Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms. 2021 , 44, 61-68		5
95	Probiotic-prebiotic-synbiotic modulation of (YAP1, LATS1 and NF2 mRNAs/miR-1205/lncRNA SRD5A3-AS1) panel in NASH animal model. 2021 , 140, 111781		1
94	Effect of Lycium barbarum polysaccharide supplementation in non-alcoholic fatty liver disease patients: study protocol for a randomized controlled trial. 2021 , 22, 566		5
93	Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases. 2021 , 35, e21871		5
92	The Effect of Probiotics (MCP BCMC Strains) on Hepatic Steatosis, Small Intestinal Mucosal Immune Function, and Intestinal Barrier in Patients with Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2021 , 13,	6.7	8
91	Probiotic and prebiotic interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. 2021 , 12, 517-529		0
90	Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases. <i>World Journal of Gastroenterology</i> , 2021 , 27, 6161-6179	5.6	2
89	Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease. 2021 , 123, 154844		4
88	The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2021 , 27, 22-43	6.9	14
87	Immunity and Gut Microbiome: Role of Probiotics and Prebiotics. <i>Microorganisms for Sustainability</i> , 2021 , 61-83	1.1	0

86	The interplay between host cellular and gut microbial metabolism in NAFLD development and prevention. 2021 , 131, 564-582		3
85	Nanoprotobiotics: When Technology Meets Gut Health. 2020 , 389-425		3
84	Microbiota, NASH, HCC and the potential role of probiotics. 2017 , 38, 231-240		113
83	An Accessible and Pragmatic Experimental Model of Nonalcoholic Fatty Liver Disease. <i>Middle East Journal of Digestive Diseases</i> , 2016 , 8, 109-15	1.1	16
82	[Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation]. <i>Terapevticheskii Arkhiv</i> , 2017 , 89, 120-128	0.9	4
81	The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. <i>Advanced Pharmaceutical Bulletin</i> , 2020 , 10, 542-555	4.5	3
80	Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view. <i>World Journal of Gastroenterology</i> , 2020 , 26, 1901-1911	5.6	11
79	Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management. <i>World Journal of Gastroenterology</i> , 2020 , 26, 6514-6528	5.6	9
78	Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial. <i>Journal of Research in Medical Sciences</i> , 2016 , 21, 106	1.6	21
77	Egg consumption and risk of non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2017 , 9, 503-509	5.09	23
76	Influence des pr̄let probiotiques sur le poids. <i>Pratiques En Nutrition</i> , 2015 , 11, 25-29	0	
75	Non-alcoholic Fatty Liver Disease in Obesity. 2016 , 159-179		
74	S̄ndrome metab̄lica e Doen̄a Hep̄tica Gordurosa N̄o Alcōlica (DHGNA). 139-184		
73	Daily Consumption of the Capparis spinosa Reduces Some Atherogenic Indices in Patients with Non-alcoholic Fatty Liver Disease: A Randomized, Double-blind, Clinical Trial. <i>Iranian Red Crescent Medical Journal</i> , 2018 , In Press,	1.3	0
72	Nigella sativa and Non-Alcoholic Fatty Liver Disease: A Review of the Current Evidence. <i>Hepatitis Monthly</i> , 2018 , In Press,	1.8	
71	Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?. <i>Clinical and Molecular Hepatology</i> , 2018 , 24, 299-301	6.9	
70	Gut microbiata: underestimated or exaggerated?. <i>Mucosa</i> , 2018 , 1, 30-35	0.1	
69	Have Probiotics and Synbiotics passed the test of time to be implemented in management of obesity and related metabolic disorders-a comprehensive review. <i>Advances in Obesity Weight Management & Control</i> , 2019 , 9, 21-28	0.3	0

68	Fructose Consumption is Associated with Non-Alcoholic Fatty Liver Disease Risk: A Case-Control Study from Iran. <i>Hepatitis Monthly</i> , 2019 , In Press,	1.8	0
67	Intestinal microbiota in children with obesity. Role of probiotics. <i>Meditinskiy Sovet</i> , 2020 , 134-142	0.4	
66	Gut Microbiota, Glucose, Lipid, and Water-Electrolyte Metabolism in Children With Nonalcoholic Fatty Liver Disease. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021 , 11, 683743	5.9	6
65	EFFECTS OF SYNBIOTIC SUPPLEMENTATION ON GUT FUNCTIONING AND SYSTEMIC INFLAMMATION OF COMMUNITY-DWELLING ELDERLY - SECONDARY ANALYSES FROM A RANDOMIZED CLINICAL TRIAL. <i>Arquivos De Gastroenterologia</i> , 2020 , 57, 24-30	1.3	2
64	Probiotics for Human Health. <i>Microorganisms for Sustainability</i> , 2021 , 181-212	1.1	3
63	Gut microbiota and obesity: an overview of microbiota to microbial-based therapies.. <i>Postgraduate Medical Journal</i> , 2022 ,	2	2
62	The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease.. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	4
61	Non-alcoholic fatty liver disease: Epidemiology, pathophysiology and an update on the therapeutic approaches. <i>Asian Pacific Journal of Tropical Biomedicine</i> , 2022 , 12, 99	1.4	0
60	Serum CathepsinD in pregnancy: Relation with metabolic and inflammatory markers and effects of fish oils and probiotics.. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022 ,	4.5	
59	The effect of daily consumption of probiotic yogurt on liver enzymes, steatosis and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD): study protocol for a randomized clinical trial.. <i>BMC Gastroenterology</i> , 2022 , 22, 102	3	1
58	The association between dietary acid load and odds of non-alcoholic fatty liver disease: A case-control study.. <i>Nutrition and Health</i> , 2022 , 2601060221088383	2.1	
57	Potential Roles of the Gut Microbiota in Pancreatic Carcinogenesis and Therapeutics.. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022 , 12, 872019	5.9	0
56	Gut Microbiota and Complications of Type-2 Diabetes.. <i>Nutrients</i> , 2021 , 14,	6.7	11
55	Gut microbiota and obesity. Can probiotics help?. <i>PediatrīConsilium Medicum</i> , 2021 , 330-334	1.3	
54	Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota.. <i>Nutrients</i> , 2021 , 14,	6.7	4
53	Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets.. <i>Biomedicines</i> , 2021 , 10,	4.8	2
52	Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System.. <i>Frontiers in Medicine</i> , 2021 , 8, 781567	4.9	0
51	Efficacy of the Synbiotic Supplementation on the Metabolic Factors in Patients with Metabolic Syndrome: A Randomized, Triple-Blind, Placebo-Controlled Trial. <i>International Journal of Clinical Practice</i> , 2022 , 2022, 1-11	2.9	1

50 Image_1.jpg. **2018,**

49 Image_2.jpg. **2018,**

48 Table_1.docx. **2018,**

47 Table_2.docx. **2018,**

46 Image_1.TIF. **2020,**

45 Image_2.TIF. **2020,**

44 Table_1.XLSX. **2020,**

43 Periodontal Disease and Nonalcoholic Fatty Liver Disease: New Microbiome-Targeted Therapy Based on the Oral-Gut-Liver Axis Concept. *Current Oral Health Reports*, 1 1.2 0

42 Review article: the future of microbiome-based therapeutics. *Alimentary Pharmacology and Therapeutics*, 6.1 2

41 Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease. *Computational and Mathematical Methods in Medicine*, **2022**, 2022, 1-15 2.8 1

40 Mechanisms behind the Role of SIBO in Non-Alcoholic Fatty Liver Disease: An Interplay between Liver, Gut Microbiota and Nutrition. *Current Nutrition and Food Science*, **2022**, 18, 0.7

39 Effects of Synbiotics, Probiotics, and Prebiotics on Liver Enzymes of Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. *Frontiers in Nutrition*, **2022**, 9, 6.2 0

38 Synbiotics: a New Route of Self-production and Applications to Human and Animal Health. *Probiotics and Antimicrobial Proteins*, 5.5 1

37 Research progress of gut microbiota in hepatocellular carcinoma. *Journal of Clinical Laboratory Analysis*, 3 0

36 Effects of prebiotics in combination with probiotics on intestinal hydrolase activity, microbial population and immunological biomarkers in SD rats fed an AIN-93G diet. *Laboratory Animal Research*, **2022**, 38, 1.9

35 Synbiotic Effects of Fermented Rice on Human Health and Wellness: A Natural Beverage That Boosts Immunity. *Frontiers in Microbiology*, 13, 5.7 1

34 Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases. *Clinical and Molecular Hepatology*, **2022**, 28, 425-472 6.9 0

33 Dietary Component-Induced Inflammation and Its Amelioration by Prebiotics, Probiotics, and Synbiotics. *Frontiers in Nutrition*, 9, 6.2 1

- 32 Gut Microbiota: A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review. *International Journal of Molecular Sciences*, **2022**, 23, 8307 6.3 ○
- 31 A food-grade nanoemulsion for delivering probiotics and prebiotics. **2022**, 347-361 ○
- 30 Effects of gut microbiota and gut-derived lipopolysaccharide on patients with coronary heart disease. ○
- 29 Age-Related NAFLD: The Use of Probiotics as a Supportive Therapeutic Intervention. **2022**, 11, 2827 ○
- 28 Effects of Time-Restricted Feeding (16/8) Combined with a Low-Sugar Diet on the Management of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. **2022**, 111847 ○
- 27 Prebiotics and Probiotics in Regulation of Metabolic Disorders. **2022**, 239-269 ○
- 26 Therapeutic Effects and Mechanisms of Action of Garlic (*Allium sativum*) on Nonalcoholic Fatty Liver Disease: A Comprehensive Systematic Literature Review. **2022**, 2022, 1-15 ○
- 25 Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: a double-blind placebo-controlled randomized study. **2022**, 100769 ○
- 24 Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease. 13, 2
- 23 Advances in research of microbiome regulation as a therapy for liver failure. **2022**, 30, 971-977 ○
- 22 Gut microbiome determines therapeutic effects of OCA on NALFD by modulating bile acid metabolism. ○
- 21 Microbiome-Targeted Therapies as an Adjunct to Traditional Weight Loss Interventions: A Systematic Review and Meta-Analysis. Volume 15, 3777-3798 ○
- 20 Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). 13, ○
- 19 Prebiotic and Synbiotic Foods. **2022**, 75-112 ○
- 18 Metabolic-associated fatty liver disease: pharmacological management. **2023**, 319-341 ○
- 17 Efficacy of probiotics on nonalcoholic fatty liver disease: A meta-analysis. **2023**, 102, e32734 ○
- 16 Effect of Dietary Intervention, with or without Cointerventions, on Inflammatory Markers in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. **2023**, ○
- 15 Alginate Oligosaccharides Repair Liver Injury by Improving Anti-Inflammatory Capacity in a Busulfan-Induced Mouse Model. **2023**, 24, 3097 ○

- 14 Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP). **2023**, 189, 106679 ○
- 13 Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis. 29, 967-996 ○
- 12 Effects of SCFAs and TMAO on non-alcoholic fatty liver disease indicating the therapeutic benefits of plant-based diet, and supplemental prebiotics, probiotics and synbiotics. **2023**, 66, ○
- 11 Dairy product consumption was associated with a lower likelihood of non-alcoholic fatty liver disease: A systematic review and meta-analysis. 10, ○
- 10 Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis. 10, ○
- 9 Nutrition in liver disease. **2023**, 87-134 ○
- 8 Role of immune responses for development of NAFLD-associated liver cancer and prospects for therapeutic modulation. **2023**, ○
- 7 Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?. **2023**, 29, 377-380 ○
- 6 Microbiome-liver crosstalk: A multihit therapeutic target for liver disease. 29, 1651-1668 ○
- 5 Synbiotics in the Management of Breast Cancer. **2023**, 289-304 ○
- 4 Understanding the Role of Synbiotics in Prevention and Management of Cervical Cancer. **2023**, 329-340 ○
- 3 Nutrition et stéatose hépatique. **2023**, ○
- 2 Synbiotics as Supplemental Therapy for the Alleviation of Chemotherapy-Associated Symptoms in Patients with Solid Tumours. **2023**, 15, 1759 ○
- 1 Probiotics as Potential Therapy in the Management of Non-Alcoholic Fatty Liver Disease (NAFLD). **2023**, 9, 395 ○